Annual Health Care Summit

Event Sections

European health care systems are at a crossroads. Regarded for decades as a source of pride and consistently topping world rankings for patient access and quality of care, the systems are under pressure from a perfect storm of aging populations, migratory influx, and strained public budgets. At the same time, an unprecedented wave of technological innovation is transforming health care, from new types of medicines to health apps, connected medical devices, and the big data revolution. These technologies present their own concerns over cost, patients’ privacy and the security of sensitive information.

EU and national governments are working to optimize the European regulatory framework and capitalize on innovative technologies to achieve effective, innovative and sustainable health care systems. Our Health Care Summit, brought to you by POLITICO and Le Tempson October 11, 2016 (9:00 AM-3:20 PM), will feature the international policymakers, industry leaders, global health organizations, trade associations and biotech start-ups that are driving healthcare in Europe, to set a roadmap for the future.

The WHO’s response to the Ebola outbreak has been criticized for a lack of integration between its health emergency and humanitarian response systems. What is the status of the WHO’s efforts to reform? What role should EU member states play? What are the key challenges to overcome?

Introductory Remarks: Mary Harney, Chair, EUROPEAN STEERING GROUP ON SUSTAINABLE HEALTHCARE, Former Health Minister of Ireland and Former Deputy Prime Minister of Ireland

Tackling cross-border health threats like infectious diseases or antimicrobial resistance requires coordiantion. Will efforts to ensure a coordinated approach throughout the EU enhance its ability to influence global public health policy? How does the Brexit vote and the view by some that the EU should stick to its core competences impact these efforts?

More health data is available through clinical trials, e-health records, and consumer apps, opening up the potential for faster and better diagnosis and cures. But with it comes concerns about privacy and security, device interoperability and patient safety. How can connected health maximize efficiency? How can big data be integrated into health care decision-making? Who is responsible for developing consumer e-health literacy?

Jackie Ahr, Acting Secretary General, EUROPEAN COUNCIL ON MEDICAL ORDERS

Miguel Gonzalez-Sancho Bodero, Head of Unit for eHealth, Wellbeing and Aging, DG CNECT, EUROPEAN COMMISSION

Increasing global access to essential medicines and narrowing the vaccination gap between developed and developing countries means surmounting numerous supply-side barriers. What are the optimal conditions for public-private partnerships to deliver drug and vaccine development? How should risks and costs be shared between the public and private sector?

How can the EU, national governments and supply-chain stakeholders advance efforts to close the immunization gap and address vaccine skepticism in Europe? What is the best way to empower and educate patients to make the best decisions for their health?

Peggy Maguire, Director General, EUROPEAN INSTITUTE OF WOMEN’S HEALTH, Board Member and Former President, EUROPEAN PUBLIC HEALTH ALLIANCE

2:50 PM CET

Interview: What Can Be Done to Combat Anti-Microbial Resistance?

Antibiotic resistance claims 50,000 lives in the US and Europe alone. According to Dutch Health Minister Edith Schippers, antibiotic resistance risks “undoing nearly a century of medical progress.” What action plans are necessary at the national and EU levels? How can collaboration between stakeholders, particularly public-private partnerships, make a difference?

Keiji Fukuda, Special Representative for Antimicrobial Resistance, WORLD HEALTH ORGANIZATION

Canice Nolan, Minister Counselor for Health and Food Safety, EU DELEGATION TO THE UNITED NATIONS

3:20 PM CET

Closing Remarks and End of Session

Speakers

Jackie Ahr, Acting Secretary General, European Council on Medical Orders

Jackie Ahr is Acting Secretary General of the European Council On Medical Orders (CEOM). A French and Swiss national, he has worked as a general practitioner in the French region of Champagne since 1969. Ahr has been active in the regulation of the medical profession at the European and International levels since 1991 and is the current Treasurer of the French Medical Council. He has participated in the drafting of various publications on e-health and m-health both in France and at the European level. To Ahr, engagement with the regulation of the medical profession means to adapt constantly and to cooperate with the other health professions, European Chambers of Doctors and national and European Institutions.

Richard Bergström has been the Director General of the European Federation of Pharmaceutical Industries and Associations (EFPIA) since April 2011. Previously he served for nine years as the Director-General of LIF, the Swedish Association of the Pharmaceutical Industry, following positions in Switzerland in regulatory affairs at the pharmaceutical companies Roche and Novartis. Mr Bergström was also appointed by the Swedish Government to the Board of the Karolinska Institute. He is a pharmacist by training, receiving his MScPharm degree from the University of Uppsala, Sweden in 1988.

Roberto Bertollini, Richard von Weizsäcker Fellow

Roberto Bertollini is the Richard von Weizsacher Fellow at the Robert Bosch Academy. He also advises the WHO on public health policy and the relationship with the EU. Bertollini served as the WHO Representative to the EU in Brussels and Chief Scientist of the WHO Regional Office for Europe from October 2011 – July 2016. Before that, he occupied senior management positions in WHO both at the Regional Office for Europe and at the headquarters in Geneva in 1991 when he joined the Organization. Earlier in his career he worked at the Epidemiology Unit of the Lazio Region of Italy. During his professional experience he has carried out missions in several European and African countries, supporting the implementation of health cooperation projects. Bertollini holds a degree in Medicine and a postgraduate degree in pediatrics, as well as a master’s in public health which he obtained from Johns Hopkins University.

Finn Børlum Kristensen, Professor of Health Services Research and Health Technology Assessment, University of Southern Denmark

Finn Børlum Kristensen is a Professor of Health Services Research and Health Technology Assessment (HTA) at the Faculty of Health Sciences, University of Southern Denmark. He also advises the European Commission on HTA. From 2006 – 2016, Kristensen was Secretariat Director of the European Network for HTA, EUnetHTA, in the Danish Health Authority. He publishes frequently in scientific journals and is editor of a health technology assessment handbook. He was Chairman of the International Network of Agencies for HTA (INAHTA) 2003-06 and is Chairman of the HTA Council in the International Society ISPOR since 2013. He is a sought-after expert adviser and speaker to the European Commission, individual countries and healthcare stakeholders. Kristensen was head of Danish Centre for HTA (DACEHTA) from its establishment in 1997 to 2009. He has a PhD in Epidemiology and has been professor in health services research and HTA at University of Southern Denmark since 1999. He has a clinical background as a primary care physician and is a medical specialist in public health.

Agnès Buzyn, Chair, French National Authority for Health (HAS)

Agnès Buzyn is Professor of Hematology at the University Pierre-and-Marie-Curie in Paris. She was appointed Chairwoman of the French National Authority for Health (HAS - Haute Autorité de santé). Buzyn was President of the French National Cancer Institute (INCa) from May 2011 until February 2016. From 2008 to 2013, she served as Chair of the Executive Board of the Radioprotection and Nuclear Safety Institute (IRSN) and since 2009 she has been a member of the Atomic Energy Committee. From 2002 to 2006, Buzyn was the director of a research team on tumor immunology at the National Institute of Health and Medical Research (INSERM) - Institut Cochin-Paris Descartes. Before that, as an academic hematologist and clinician at the University Paris Descartes - Necker Hospital, from 1992 to 2011 she headed the Adult Hematology Intensive Care and Bone Marrow Transplants Unit. Buzyn received an MD from University Pierre-and-Marie-Curie in Paris and a PhD in immunology from the University Paris Descartes.

Laurent Chokoualé Datou is Chairman of Weber Shandwick’s EU Public Affairs practice. He has over 24 years’ experience delivering public affairs and strategic communications support and advice to clients in the corporate, trade association, government and not-for-profit arenas – at EU institution and country level. A lawyer by training, he also has long-standing experience in managing the public affairs and government relations aspects of major EU M&A and antitrust reviews. His sector experience spans aviation, financial services, food and drink, telecoms/ICT, financial services and health and pharmaceuticals. Client experience includes Orange France Télécom, Barclays Bank, British Airways, Danone, The Coca-Cola Company, Total, Shell, Novartis and Roche. Prior to joining Weber Shandwick, Laurent was Managing Director of Edelman’s Brussels office and before that, Managing Director of APCO Worldwide’s Brussels office.

Francesca Colombo, Head of Health Division, OECD

As Head of the OECD Health Division, Francesca Colombo oversees OECD work on health, which aims at providing internationally comparable data on health systems and applying economic analysis to health policies, advising policy makers, stakeholders and citizens on how to respond to demands for more and better health care. Mrs Colombo has over 15 years of experience leading projects on the performance of health systems on a wide range of topics. Over her career, she travelled extensively in Europe, South America and Asia, advising governments on health system policies and reforms.

Mark Dybul has been the Executive Director of the Global Fund to Fight AIDS, Tuberculosis and Malaria since 2013. He has worked on HIV and public health for more than 25 years as a clinician, scientist and teacher. He became a founding architect and driving force in the implementation of the US President’s Emergency Plan for AIDS Relief, (PEPFAR). From 2006 until 2009, Dybul served as Chief Medical Officer, Assistant, Deputy and Acting director, before he was appointed as its leader, becoming U.S. Global AIDS Coordinator, with the rank of Ambassador at the level of an Assistant Secretary of State.

Hans-Georg Eichler, Senior Medical Officer, European Medicines Agency

Hans-Georg Eichler is the Senior Medical Officer at the European Medicines Agency (EMA). Before joining EMA, Eichler was at the Medical University of Vienna in Austria for 15 years. In 2011, Eichler was the Robert E. Wilhelm Fellow at the Massachusetts Institute of Technology’s Center for International Studies, participating in a joint research project under MIT’s NEWDIGS initiative. He has been Vice-Rector for Research and International Relations since 2003, and Professor and Chair of the Department of Clinical Pharmacology since 1992. Before he served as President of the Vienna School of Clinical Research and Co-Chair of the Committee on Reimbursement of Drugs of the Austrian Social Security Association. He has industry experience at Ciba-Geigy Research Labs, and Outcomes Research at Merck & Co. Eichler received an MD from Vienna University Medical School and a MS in Toxicology from the University of Surrey. He trained in internal medicine and clinical pharmacology at the Vienna University Hospital and at Stanford University.

Josep Figueras, Director, European Observatory on Health Systems and Policies

Josep Figueras is the Director of the European Observatory on Health Systems and Policies. He is currently a visiting professor at Imperial College, London. His research focuses on comparative health system and policy analysis and is Editor of the European Observatory series published by Open University Press. Figueras is Honorary Fellow of the UK faculty of Public Health Medicine and a member of the board of the Agency for Public Health Education Accreditation (APHEA). He has also served other major multilateral organizations such as the European Commission and the World Bank. Figueras has been twice awarded the European Health Management Association (EHMA) prize and in 2006 received the Andrija Stampar Medal. Before he was head of the MSc in Health Services Management at the London School of Hygiene & Tropical Medicine.

Keiji Fukuda, Special Representative for Antimicrobial Resistance, World Health Organization

Keiji Fukuda is Special Representative for Antimicrobial Resistance for the Director-General at the
World Health Organization (WHO). He previously served as the Assistant Director-General for Health
Security, the Special Adviser on Pandemic Influenza to the Director-General; and Director of the
Global Influenza Programme. Before joining WHO, Fukuda served as the Chief of the Epidemiology Unit,
Influenza Branch, Centers for Disease Control and Prevention (CDC) in the United States. He has
extensive global and national public health experience with health security and emerging infectious
diseases. He is currently focusing on shaping the global approach to antimicrobial resistance. Dr
Fukuda is a physician and epidemiologist and received his MD from the University of Vermont, his MPH from the University of California, Berkeley and additional training in epidemiology at CDC.

Miguel González-Sancho Bodero, Head of Unit for eHealth, Wellbeing and Ageing, DG CNECT, EUROPEAN COMMISSION

Miguel González-Sancho has been Head of the Unit for eHealth, Well-Being and Ageing in the European Commission’s department for Communication Networks, Content and Technology (DG CNECT) department since July 2016. He previously held different positions in DG CNECT, including head of unit for administration and finance, deputy head of unit for policy coordination and deputy head of the unit ICT for Inclusion. During this period, he worked on successive policy strategies (e-Europe, i20210, and Digital Agenda) as well as policy initiatives and R&D&I projects on ICT for social inclusion, accessibility, public services and skills. González-Sancho was also a member of private office of the European Commission Vice-President for the Digital Agenda, Neelie Kroes. Before that, he worked as legal officer on telecommunications regulation, and as handler of Trade Defense Investigations in DG TRADE. He holds degrees in Law (UNED, Spain) and International Relations (UCL, Belgium) as well as three master degrees: in finance management, audit and accounting; business administration; European policies.

Mary Harney, Chair, European Steering Group on Sustainable Health Care

Mary Harney is Chair of the European Steering Group on Sustainable Health Care. She is the former Deputy Prime Minister and former Health Minister of Ireland. An economics graduate of Trinity College Dublin, she had a long and successful career in politics, serving both in the Senate and in the lower chamber of parliament. In 1997, Harney was appointed Minister for Enterprise, Trade and Employment. She also served as Deputy Prime Minister for almost 10 years. In 2004, she was appointed Minister for Health and Children, a position she held until her retirement from politics in 2011. Harney chairs AMBER, a Bioengineering Research Centre at Trinity College Dublin, bridging research and industry and is an EFPIA Advisory Board member. She is also a director of the Hospice Foundation of Ireland as well as several companies in Ireland and abroad.

Susan-Jane Herbert, Head of Marketing and Strategy Operations, MERCK

Susan-Jane Herbert is Head of Marketing and Strategy Operations at Merck. In this position she is responsible for all partnering activities, taking the global lead role for identifying and executing Global Business Development opportunities for Merck Biopharma’s R&D, and also its commercial portfolio. Susan Herbert joined Serono International S.A. in Geneva, Switzerland, in 1988. Prior to Serono’s acquisition by Merck in 2007, she held various senior positions in both the Diagnostics and Pharmaceutical Divisions, covering in R&D, Regulatory Affairs, Manufacturing and Development. During her career she has been instrumental in the closing of key deals for Merck. Susan graduated from the University Manchester, UK, with a Master’s degree in Biochemistry and Doctorate degree from the Faculty of Medicine.

Ulrike Kreysa, Vice-President, Healthcare, GS1 Global Office

Ulrike Kreysa is responsible for the Healthcare sector at the GS1 Global Office, a company specializing in a global system of standards, and works in 112 countries to develop and implement GS1 standards in the healthcare industry. Having started her career as a pharmacist, she manages GS1 Healthcare, the global GS1 user group, formed by stakeholders in the healthcare supply chain, including pharmaceutical and medical device manufacturers, wholesalers/distributors, general purchasing organizations, hospitals, pharmacies, logistic providers, governmental and regulatory bodies and associations.

Peggy Maguire, Director General, European Institute of Women’s Health

Peggy Maguire has been Director General of the European Institute of Women’s Health (Ireland) since February 1996. Maguire has twenty years’ experience working in the health sector at European and national level. As an advocate for a health literate public, she developed Cancom, a cancer communication and information initiative for women and families. Previously, she was Director of development at the National Maternity Hospital from 1992 to 1996 where she initiated the first women’s health survey in Ireland ”Women's Health in Ireland –Attitudes and Behaviour”. She also worked at the Irish College of General Practitioners (ICGP) as Director of the research foundation working with 32 GP faculties to promote and develop the research unit of the ICGP. Maguire has served as a member of many expert groups including the WHO Expert group on a Women’s Health Strategy for Europe, and is currently a member of the European Commission Horizon 2020 Advisory Group on gender and Horizon 2020 Advisory Group for societal challenge 1: Demographic change, health and wellbeing. She was a founding member of the Women's Health Council in Ireland. She is currently board member of the European Public Health Alliance after having been President.

Michael Makanga, a clinician-scientist with 25 years of professional experience of working on health and poverty-related diseases in sub-Saharan Africa, is the Executive Director of the European & Developing Countries Clinical Trials Partnerships (EDCTP). This includes 21 years of work experience on medical product development and clinical regulatory activities. Before joining EDCTP, Makanga first worked in clinical practice and academia, and later clinical research. He has worked with EDCTP for 12 years in different management capacities. Moreover, he has served in various scientific and policy advisory boards for international product development and philanthropic organizations along with pharmaceutical companies involved in developing medicinal products for poverty related and neglected diseases. He holds a medical degree from Makerere University and has been in various clinical and research positions before and after undertaking a master’s degree at the University of Liverpool, and then a PhD at the Liverpool School of Tropical Medicine. He is also a Fellow of the Royal College of Physicians.

Rohit Malpani is Director of Policy and Analysis at Médecins Sans Frontières’ (MSF) Access Campaign. Before that, Malpani was Special Adviser, Policy and Campaigns Unit for Oxfam Hong Kong. Previously, he served as Senior Campaigns Adviser at Oxfam America, where he managed Oxfam's “access to medicines” campaign, provided advice to Oxfam on the intersection of intellectual property and development, and also served as a corporate campaigns adviser with Oxfam America's Private Sector Department. Previously, he worked as a human rights adviser to the World Health Organization and the International Labor Organization, and also with local civil society groups in Thailand and Argentina. Malpani started his legal career as an intellectual property attorney with the law firm of Wilson, Sonsini, Goodrich and Rosati. He holds a DJur from New York University School of Law and a Bachelor of Arts from Rice University.

Canice Nolan, Minister Counselor for Health and Food Safety, EU Delegation to the United Nations

Canice Nolan is the Minister Counselor responsible for health and food safety at the EU Delegation to the United Nations in Geneva. He joined the European Commission in 1991 working at the Directorate General for Research and Innovation. In 1997 Nolan moved to the Directorate General for Agriculture and Rural Development and was responsible for the assessment and legislation on pesticides and their residues. Nolan has been with the Directorate General of Food Safety, Health and Consumer Affairs since 1998. In 2004 he served in the EU Delegation to the USA, and from 2005 – 2008 Nolan was Head of Food Safety, Health and Consumer Affairs. Until recently, he served as Senior Coordinator for Global Health. Nolan has a PhD in toxicology from University College Dublin.

Michel Pettigrew, President of the Executive Board & Chief Operating Officer, Ferring Group

Michel Pettigrew is the President of the Executive Board for the Ferring Group, a research driven, biopharmaceutical company, after having joined in May 2001, and in addition, manages all commercial, global marketing, business development, product supply, research, development and regulatory activities of the company. He is also Chairman of Ferring Holding Inc, Ferring’s largest subsidiary. Before his arrival at Ferring, Pettigrew held several senior management positions throughout the world during a long career with Bristol-Myers Squibb. Pettigrew has a bachelor of commerce degree from McGill University where he also plays an active role with the McGill Desautels Faculty of Management Alma Matter, and an MBA from York University.

Gabriella Pravettoni is Patient Empowerment Lead at the European Alliance for Personalized Medicine. She is Full Professor of Psychology of Decision Making at the University of Milan, where she also serves as Deputy Director of the Department of Oncology and Hemato-oncology (DIPO) and President of the Degree Programme of Cognitive Science and Decision making. Alongside this, Pravettoni is Director of the Psychoncology Division at the European Institue of Oncology in Milan and Coordinator of Doctorate Folsatec (Foundations of the life sciences and their ethical consequences) at SEMM (European School of Molecular Medicine), Milan. She is a visiting Professor at King's College, London and a Member of the ecancer Scientific Board, UK. Pravetonni’s main research activities are conducted at the European Institute of Oncology, both at a national and international level. They focus on medical humanities as the main concern is patient empowerment and wellbeing, cognitive processes, decisions in medicine at errors prevention.

Peter Salama is the Executive Director of WHO’s Health Emergencies Programme. Before joining the WHO, he was UNICEF’s Regional Director for the Middle East and North Africa. Salama has led UNICEF’s global response to Ebola, served as UNICEF Representative in Ethiopia and Zimbabwe (2009-2015), UNICEF’s Chief of Global Health and Principal Advisor on HIV/AIDS based at headquarters in New York (2004-2009), and UNICEF’s Chief of Health and Nutrition in Afghanistan (2002-2004). Before this, he was visiting scientist at the International Emergency and Refugee Health Branch at the US Center for Disease Control (CDC), and a visiting professor in nutrition at Tufts University. He has also worked with Doctors without Borders and Concern Worldwide. Salama is a medical epidemiologist with medical and public health degrees from Melbourne and Harvard Universities, where he was also a Fulbright and Harkness fellow in public policy.

Become a speaker

For more information on becoming a speaker for a POLITICO event, contact us online.

Moderators

Kim Dixon, News Editor, Health & Policy, Politico

Kim Dixon joins POLITICO’s Brussels team after a year and a half leading the Washington bureau’s tax policy team, a topic she covered for about seven years.
Dixon, a University of Pennsylvania and Columbia Journalism School grad, is excited to be returning to health policy, where she got her start.
She cut her teeth covering the Food and Drug Administration, where she broke news on drugmakers’ compliance – and lack of – with FDA rules, and public health, including the anthrax scare after Sept. 11.
Dixon also spent five years dissecting the finances of for-profit health insurance and hospital companies, including their attempts to tame medical costs in the run-up to Obamacare.

Olivier Dessibourg, Science Editor, Le Temps

Olivier Dessibourg is an award-winning science and technology journalist and editor, heading the Science section at the Ringier Axel Springer Switzerland newsroom for the swiss daily Le Temps and the newsmagazine L’Hebdo, covering all fields from hard sciences to health and environment. A physicist, mathematician and science teacher by training, he is the current president of the Swiss Association of Science Journalism (350 members), and the swiss delegate to the World Federation of Science Journalists. His articles also appeared in NewScientist (UK), Le Monde and La Recherche (France), Le Soir (Belgium) and NZZamSonntag (Switzerland).

Peter O’Donnell, Contributing Editor, Politico

Peter O’Donnell has been covering European and international affairs as a freelance for more than twenty-five years – on stories ranging from the birth of the Euro and the enlargement of Europe to research policy or the Balkan wars. In Brussels he has written for The Financial Times, The Sunday Times, Reuters, the Economist Intelligence Unit, and UPI, among other media outlets in Europe and beyond, as well as doing tv and radio work for clients including the BBC, Euronews and ViEUws. He was editor-in-chief of Europe Information Service, and was associate editor of European Voice. In addition to his work as a journalist, he has acted as editor, editorial adviser and speechwriter for numerous clients in the corporate, political and academic world. He frequently chairs EU-level policy debates across Europe, and lectures on EU affairs and journalism.

Our Sponsors

Ferring Pharmaceuticals

Headquartered in Switzerland, Ferring Pharmaceuticals is a research-driven, specialty biopharmaceutical group active in global markets. The company identifies, develops and markets innovative products in the areas of reproductive health, urology, gastroenterology, endocrinology and orthopaedics. Ferring has its own operating subsidiaries in nearly 60 countries and markets its products in 110 countries. To learn more about Ferring or its products please visit www.ferring.com.

Merck

Merck is a leading science and technology company in healthcare, life science and performance materials. Around 50,000 employees work to further develop technologies that improve and enhance life. Founded in 1668, Merck is the world’s oldest pharmaceutical and chemical company. The founding family remains the majority owner of the publicly listed corporate group. To learn more about Merck please visit www.merck.com.

Roche

Roche is the world’s largest biotech company, with truly differentiated medicines in oncology, immunology, infectious diseases, ophthalmology and diseases of the central nervous system. Roche is also the world leader in in vitro diagnostics and tissue-based cancer diagnostics, and a frontrunner in diabetes management. The combined strengths of pharmaceuticals and diagnostics under one roof have made Roche the leader in personalized healthcare – a strategy that aims to fit the right treatment to each patient in the best way possible. For more information, please visit www.roche.com.

AbbVie

AbbVie is a global, research-based biopharmaceutical company formed in 2013 following separation from Abbott Laboratories. The company’s mission is to use its expertise, dedicated people and unique approach to innovation to develop and market advanced therapies that address some of the world’s most complex and serious diseases. Together with its wholly-owned subsidiary, Pharmacyclics, AbbVie employs more than 28,000 people worldwide and markets medicines in more than 170 countries. For further information on the company and its people, portfolio and commitments, please visit www.abbvie.com and follow us on Twitter @abbvie .

Dentons

Dentons is the world’s first polycentric global law firm. A top 20 firm on the Acritas 2015 Global Elite Brand Index, the Firm is committed to challenging the status quo in delivering consistent and uncompromising quality and value in new and inventive ways. Driven to provide clients a competitive edge, and connected to the communities where its clients want to do business, Dentons knows that understanding local cultures is crucial to successfully completing a deal, resolving a dispute or solving a business challenge. Now the world’s largest law firm, Dentons’ global team builds agile, tailored solutions to meet the local, national and global needs of private and public clients of any size in more than 125 locations serving 50-plus countries. . To learn more about Dentons please visit www.dentons.com.

Weber Shandwick

Weber Shandwick is a leading global communications and engagement firm in 78 cities across 34 countries with a network extending to 126 cities in 81 countries. The firm’s diverse team of strategists, analysts, producers, designers, developers and campaign activators has won the most prestigious awards in the world for innovative, creative approaches and impactful work, including being honoured as PRWeek’s Global Agency of the Year in 2015 and 2016, an Ad Age A-List Agency in 2014 and 2015, and The Holmes Report’s Global Agency of the Year in 2010, 2012, 2014 and 2015. Weber Shandwick and its Prime unit have won a combined 31 Cannes Lions since 2009 and are credited as PR agency on an additional 25 Lions. Weber Shandwick was also named a Best Place to Work by Ad Age in 2014 and 2015 and PRWeek in 2013 and 2014. The firm deploys deep expertise across sectors and specialty areas, including consumer marketing, corporate reputation, healthcare, technology, public affairs, financial services, corporate social responsibility, financial communications and crisis management, using proprietary social, digital and analytics methodologies.

Our Partners

Supporting Organization

PharmaBoardroom

PharmaBoardroom is the premier website for C-Level executives, providers, consultants and regulators active in the pharmaceuticals, healthcare and life sciences sectors around the world. With hundreds of exclusive interviews featuring the main movers and shakers of the industry, free country reports, supplemented by the latest news from global markets, sector insights, and a comprehensive database of the most significant companies and business leaders in each key market, PharmaBoardroom offers an invaluable resource for those seeking to look beyond the figures.